Twin Peaks – an American chain of sports bars and restaurants goes live on Nasdaq in what is the first restaurant debut of ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its anticipated target. The US-based company sold 12 million shares of its common ...

Nasdaq reported a higher fourth-quarter profit on Wednesday, helped by strong demand for the exchange operator's financial ...

Nasdaq reported higher fourth-quarter profit on Wednesday, helped by increased demand for the exchange operator's financial ...

Smithfield Foods and its Chinese parent raised around $522 million from the U.S. pork giant's initial public offering after ...

Investors in defense stocks seem a bit nervous at the prospect, and defense stocks have been generally down over the past three months. Where to invest $1,000 right now? Our analyst team just revealed ...

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...